Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | ESRRA | P11474 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859963 | 0.90 | ESRRA (0.58) | RXFP1CYP2D6ESRRAKMT2ARAF1 | |
| SCHEMBL8027669 | 0.88 | RXFP1 (0.60) | RXFP1CYP2D6KMT2ARAF1BRAF | |
| SCHEMBL28632119 | 0.86 | RXFP1 (0.58) | RXFP1CYP2D6ESRRAKMT2AALDH1A1 | |
| SCHEMBL4689617 | 0.79 | AAK1 (0.44) | RXFP1CYP2D6ESRRAKMT2ABRAF | |
| SCHEMBL1122507 | 0.79 | BRAF (0.61) | RXFP1CYP2D6ESRRAKMT2ARAF1 | |
| SCHEMBL1900214 | 0.78 | RXFP1 (0.66) | RXFP1KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL1803952 | 0.78 | RXFP1 (0.66) | RXFP1CYP2D6KMT2AALDH1A1HPGD | |
| SCHEMBL13483433 | 0.78 | RXFP1 (0.66) | RXFP1CYP2D6KMT2AALDH1A1HPGD | |
| SCHEMBL590479 | 0.78 | RXFP1 (0.66) | RXFP1KMT2AKDM4EMAPTCDC25B | |
| SCHEMBL8029704 | 0.77 | KMT2A (0.55) | RXFP1KMT2ABRAFALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1315781-C | Preparation of 4-amino-1-naphthol ethers | BAYER CHEMICALS AG (DE) | 2007-05-16 | — | — | CN | disclosed |
| US-20050261498-A1 | Preparation of 4-amino-1-naphthol ethers | KOMOSCHINSKI JOACHIM | 2005-11-24 | — | — | US | disclosed |
| US-6964963-B2 | Preparation of 4-amino-1-naphthol ethers | BAYER AKTIENGESELLSCHAFT (DE) | 2005-11-15 | — | — | US | disclosed |
| CN-1547568-A | Method for preparing 4-amino-1-naphthol ether compound | ˹���ػ�ѧ��Ʒ�ɷ�����˾ | 2004-11-17 | — | — | CN | disclosed |
| EP-1425261-A2 | METHOD FOR PRODUCING 4-AMINO-1-NAPHTHOL ETHERS | Bayer Chemicals AG (DE) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003020686-A3 | METHOD FOR PRODUCING 4-AMINO-1-NAPHTHOL ETHERS | BAYER CHEMICALS AG (DE) | 2003-12-04 | — | — | WO | disclosed |
| US-20030083525-A1 | Preparation of 4-amino-1-naphthol ethers | LANXESS DEUTSCHLAND GMBH (DE) | 2003-05-01 | — | — | US | disclosed |
| WO-2003020686-A2 | METHOD FOR PRODUCING 4-AMINO-1-NAPHTHOL ETHERS | BAYER CHEMICALS AG (DE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261498-A1 | Preparation of 4-amino-1-naphthol ethers | NAP1L4, NAAA, NPEPPS | RXFP1 4879/4885CYP2D6 375/4885ESRRA 2802/4885 |
| US-20030083525-A1 | Preparation of 4-amino-1-naphthol ethers | NAP1L4, NAAA, NPEPPS | RXFP1 4879/4885CYP2D6 375/4885ESRRA 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.